1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOpat S.en
dc.contributor.authorCasan J.M.L.en
dc.contributor.authorWong J.en
dc.contributor.authorNorthcott M.J.en
dc.date.accessioned2021-05-14T12:32:27Zen
dc.date.available2021-05-14T12:32:27Zen
dc.date.copyright2018en
dc.date.created20190622en
dc.date.issued2019-06-22en
dc.identifier.citationHuman Vaccines and Immunotherapeutics. 14 (12) (pp 2820-2841), 2018. Date of Publication: 02 Dec 2018.en
dc.identifier.issn2164-5515en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36922en
dc.description.abstractSince the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.Copyright © 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC.en
dc.languageenen
dc.languageEnglishen
dc.publisherTaylor and Francis Inc. (325 Chestnut St, Suite 800, Philadelphia PA 19106, United States)en
dc.relation.ispartofHuman Vaccines and Immunotherapeuticsen
dc.titleAnti-CD20 monoclonal antibodies: reviewing a revolution.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/21645515.2018.1508624en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid30096012 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30096012]en
dc.identifier.source628015752en
dc.identifier.institution(Casan, Wong, Opat) Haematology Department, Monash Health, Melbourne, Australia (Northcott) Rheumatology Department, Monash Health, Melbourne, Australia (Northcott, Opat) School of Clinical Sciences, Monash University, Melbourne, Australiaen
dc.description.addressJ.M.L. Casan, Monash Haematology, level 4, 246 Clayton Rd, Clayton, VIC 3168, Australia. E-mail: joshua.casan@gmail.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCD20 immunotherapy lymphoma Monoclonal antibody obinutuzumab rituximaben
dc.identifier.authoremailCasan J.M.L.; joshua.casan@gmail.comen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

20
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.